Editing Lipodystrophy (section)

{{short description|Inability to produce or maintain healthy fat tissue}}
{{Infobox medical condition (new)
| name            = Lipodystrophie
| image           = 
| caption         = 
|
| pronounce       = 
| field           = 
| synonyms        = 
| symptoms        =
| complications   =
| onset           =
| duration        =
| types           =
| causes          =
| risks           =
| diagnosis       =
| differential    =
| prevention      =
| treatment       =
| medication      =
| prognosis       =
| frequency       =
| deaths          =
}}

'''Lipodystrophy''' syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue.<ref>{{cite journal | vauthors = Phan J, Reue K | title = Lipin, a lipodystrophy and obesity gene | journal = Cell Metabolism | volume = 1 | issue = 1 | pages = 73–83 | date = January 2005 | pmid = 16054046 | doi = 10.1016/j.cmet.2004.12.002 | doi-access = free }}</ref><ref>{{Cite web |url=http://newsroom.ucla.edu/releases/UCLA-VA-Researchers-Discover-Fat-5841 |title=UCLA/VA Researchers discover fat gene |access-date=2017-06-15 |archive-url=https://web.archive.org/web/20181006000925/http://newsroom.ucla.edu/releases/UCLA-VA-Researchers-Discover-Fat-5841 |archive-date=2018-10-06 |url-status=dead }}</ref> The medical condition is characterized by abnormal or degenerative conditions of the body's [[adipose tissue]]. A more specific term, ''[[lipoatrophy]]'' ({{ety|el|lipo|fat||dystrophy|abnormal or degenerative condition}}), is used when describing the loss of fat from one area (usually the face). This condition is also characterized by a lack of circulating [[leptin]] which may lead to [[osteosclerosis]]. The absence of fat tissue is associated with [[insulin resistance]], [[hypertriglyceridemia]], [[non-alcoholic fatty liver disease]] (NAFLD) and [[metabolic syndrome]].<ref name=":0">{{cite journal | vauthors = Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T | title = The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 101 | issue = 12 | pages = 4500–4511 | date = December 2016 | pmid = 27710244 | pmc = 5155679 | doi = 10.1210/jc.2016-2466 | url = }}</ref><ref name=":1">{{cite journal | vauthors = Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, DiPaola F, Chenevert TL, Horowitz JF, Buggs-Saxton C, Rupani AR, Thomas PE, Tayeh MK, Innis JW, Omary MB, Conjeevaram H, Oral EA | title = Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort | journal = Clinical Endocrinology | volume = 86 | issue = 5 | pages = 698–707 | date = May 2017 | pmid = 28199729 | pmc = 5395301 | doi = 10.1111/cen.13311 }}</ref>